HC Wainwright & Co. Reiterates Buy on Bicycle Therapeutics, Maintains $57 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a 'Buy' rating on Bicycle Therapeutics (NASDAQ:BCYC) and maintained a price target of $57.
August 04, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bicycle Therapeutics' stock is likely to be positively impacted by the reiterated 'Buy' rating and maintained price target of $57 by HC Wainwright & Co.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiterated 'Buy' rating and maintained price target of $57 by HC Wainwright & Co. indicates their positive outlook on Bicycle Therapeutics, which could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100